Table 3.
Immune responses as IgG antibodies against Ancestor SARS-CoV-2 Spike protein.
|
No previous booster |
One previous booster |
Two previous boosters |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Group 1 |
Group 2 |
Group 3 |
Group 4 |
Group 5 |
Group 6 |
Group 7 |
Group 8 |
Group 9 |
||
| SCB-2019 | ChAdOx1-S | BNT162b2 | SCB-2019 | ChAdOx1-S | BNT162b2 | SCB-2019 | ChAdOx1-S | BNT162b2 | ||
| Day | N = | 9 | 7 | 5 | 64 | 29 | 28 | 265* | 134 | 139 |
| 0 | GMT (IU/mL) | 5675 | 5738 | 4588 | 10021 | 7155 | 10200 | 11798 | 10662 | 12072 |
| (95 % CI) | (2471–13036) | (1644–20028) | (1151–18285) | (8423–11924) | (5201–9844) | (7324–14206) | (10456–13311) | (8992–12641) | (10289–14164) | |
| 28 | GMT (IU/mL) | 17485 | 16251 | 38314 | 17571 | 11283 | 45644 | 20277 | 13995 | 58771 |
| (95 % CI) | (10081–30327) | (8454–31239) | (22129–66337) | (14904–20715) | (8361–15226) | (33939–61387) | (18363–22390) | (11857–16520) | (51840–66629) | |
| GMFR | 3.08 | 2.83 | 8.35 | 1.75 | 1.58 | 4.47 | 1.72 | 1.31 | 4.87 | |
| (95 % CI) | (0.89–10.7) | (0.87–9.24) | (1.72–40.54) | (1.47–2.10) | (1.29–1.93) | (3.06–6.55) | (1.57–1.88) | (1.19–1.45) | (4.20–5.64) | |
| 84 | GMT (IU/mL) | 11398 | 17152 | 26114 | 15079 | 9301 | 24199 | 17484 | 11553 | 32565 |
| (95 % CI) | (7967–21864) | (9336–31512) | (14906–45750) | (12490–18203) | (6686–12939) | (16992–34463) | (15666–19513) | (9912–13467) | (28626–37046) | |
| GMFR vs Day 0 | 2.33 | 2.99 | 5.69 | 1.50 | 1.30 | 2.37 | 1.48 | 1.08 | 2.70 | |
| (95 % CI) | (0.81–6.66) | (1.30–6.89) | (1.73–18.8) | (1.23–1.83) | (0.97–1.74) | (1.72–3.27) | (1.33–1.64) | (0.96–1.22) | (2.34–3.10) | |
| GMFR vs Day 28 | 0.75 | 1.06 | 0.68 | 0.86 | 0.82 | 0.53 | 0.86 | 0.83 | 0.55 | |
| (95 % CI) | (0.47–1.22) | (0.59–1.88) | (0.38–1.21) | (0.74–1.00) | (0.64–1.06) | (0.41–0.69) | (0.79–0.93) | (0.74–0.92) | (0.50–0.62) | |
* N = 264 at Day 84.